



# SNO Digest

Weekly news from  
the Society for Neuro-Oncology

## Abstract Deadline Approaching for 2022 SNO Annual Meeting: Wednesday, June 1, 2022



The Call for Abstracts for the 2022 SNO Annual Meeting is now open! The abstract deadline is Wednesday, June 1, 2022, at 11:59pm EDT. **This deadline will not be extended.**


SNO is pleased to introduce three new submission categories for the 2022 Annual Meeting, including:

- Cancer Neuroscience
- Health Disparities and Equity
- Quality Improvement

For full conference and abstract information, please [click here](#).

For questions regarding abstracts please contact Tara Mammoser at [Tara@soc-neuro-onc.org](mailto:Tara@soc-neuro-onc.org).

## From The Journals



### From *Neuro-Oncology Practice* Inherited genetics of adult diffuse glioma and polygenic risk scores - a review

Knowledge about inherited and acquired genetics of adult diffuse glioma has expanded significantly over the past decade. Genomewide association studies (GWAS) stratified by histologic subtype identified six germline variants that were associated specifically with glioblastoma (GBM) and 12 that were associated with lower grade glioma. A GWAS performed using the 2016 WHO criteria, stratifying patients by IDH mutation and 1p/19q codeletion (as well as TERT promoter mutation), discovered that many of the known variants are associated with specific WHO glioma subtypes. [Click here to read the full article.](#)

# Educational Programming

## Early/evolving IDH wild-type glioblastoma

Dr. Maya Graham interviews Dr. David Solomon about his and his team's recent manuscript entitled: "Prospective genomically-guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes", published online in Neuro-Oncology in April 2022. [Listen to the podcast.](#)

## Neuro-Oncology

The PODCAST

## Member Submitted Clinical Question

Dr. Nicole Shonka would like to learn more about your experience using regorafenib in patients with progressive glioblastoma after treatment with bevacizumab. If you have used regorafenib in this patient population, please email Dr. Shonka ([nshonka@unmc.edu](mailto:nshonka@unmc.edu)) describing your experience and commenting on the extent and duration of response.

## SNO Career Center



### This Week's Featured Listing

The Department of Medical Oncology & Therapeutics Research at City of Hope National Medical Center is seeking a medical oncologist who has experience treating or is interested in being mentored to specialize in treating patients with sarcoma, melanoma and/or brain tumors.

[Click here to apply or see other postings!](#)

## Upcoming SNO and SNO Affiliated Events



**The 20th International Symposium of Pediatric Neuro-Oncology (ISPNO 2022)**  
June 12-15, 2022, in Hamburg  
[Register Here](#)



**2nd Annual Conference on Clinical Trials and Brain Metastases**  
August 12-13, 2022 in Toronto, Canada  
To view the program and to register [click here.](#)

## Connect With SNO on Social Media

Are you following us on our socials? We're constantly sharing the latest news and events related to the neuro-oncology field. Check us out by clicking the links below.



### SNO Digest Co-Editors

- lyad Alnahhas, MD, MSc
- Wenya Linda Bi, MD, PhD
- L. Nicolas Gonzalez Castro, MD, PhD

### SNO Team Admin Support

- Shelley Pressley - Director of Administration
- Gabrielle Griffin - Marketing and Communications Specialist

*SNO Digest is written and distributed by the Society for Neuro-Oncology. All content, including images, may not be reproduced unless permission is granted from SNO. If you would like to contribute to upcoming issues of the SNO Digest or if you have questions, please contact us at [snodigest@soc-neuro-onc.org](mailto:snodigest@soc-neuro-onc.org).*



27<sup>th</sup> Annual Meeting of the Society for Neuro-Oncology, November 16-20, 2022

Society for Neuro-Oncology | [Website](#)  
[Subscribe to the SNO Digest](#)



Society for Neuro-Oncology | PO 273296, Houston, TX 77277

[Unsubscribe megan@soc-neuro-onc.org](mailto:megan@soc-neuro-onc.org)

[Update Profile](#) | [Constant Contact Data Notice](#)

Sent by [snodigest@soc-neuro-onc.org](mailto:snodigest@soc-neuro-onc.org) in collaboration  
with



Try email marketing for free today!